Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro

Biochemical and Biophysical Research Communications

Volumn 450, Issue 4, 2014, Pages 1383-1389

  Sárvári, Anitta K ^a   Veréb, Zoltán ^a   Uray, Iván P ^b   Fésüs, László ^a,c   Balajthy, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF TEXAS   (United States)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Atypical antipsychotics; Clozapine; Inflammation; Olanzapine; Psychiatric disorders

Indexed keywords

ATYPICAL ANTIPSYCHOTICS; CLOZAPINE; INFLAMMATION; OLANZAPINE; PSYCHIATRIC DISORDERS;

ADIPOCYTES; ADIPOGENESIS; ANTIPSYCHOTIC AGENTS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; POLYMERASE CHAIN REACTION;

EID: 84906087473     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.07.005     Document Type: Article

References (30)

1. J.W. Newcomer Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 Suppl. 1 2005 1 93
2. J.W. Newcomer Metabolic considerations in the use of antipsychotic medications: a review of recent evidence J. Clin. Psychiatry 68 Suppl. 1 2007 20 27
3. W. Tan, H. Fan, and P.H. Yu Induction of subcutaneous adipose proliferation by olanzapine in rodents Prog. Neuropsychopharmacol. Biol. Psychiatry 34 2010 1098 1103
4. H.S. Vestri, L. Maianu, D.R. Moellering, and W.T. Garvey Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis Neuropsychopharmacology 32 2007 765 772
5. L.H. Yang, T.M. Chen, S.T. Yu, and Y.H. Chen Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells Pharmacol. Res. 56 2007 202 208
6. A.L. Sertie, A.M. Suzuki, R.A. Sertie, S. Andreotti, F.B. Lima, M.R. Passos-Bueno, and W.F. Gattaz Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1884 1890
7. Y.H. Lee, and R.E. Pratley The evolving role of inflammation in obesity and the metabolic syndrome Curr. Diab. Rep. 5 2005 70 75
8. J. Minet-Ringuet, P.C. Even, P. Valet, C. Carpene, V. Visentin, D. Prevot, D. Daviaud, A. Quignard-Boulange, D. Tome, and R. de Beaurepaire Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment Mol. Psychiatry 12 2007 562 571
9. A.O. Vik-Mo, J. Ferno, S. Skrede, and V.M. Steen Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells BMC Pharmacol. 9 2009 10
10. K. Hemmrich, C. Gummersbach, N. Pallua, C. Luckhaus, and K. Fehsel Clozapine enhances differentiation of adipocyte progenitor cells Mol. Psychiatry 11 2006 980 981
11. M.X. Doan, A.K. Sarvari, P. Fischer-Posovszky, M. Wabitsch, Z. Balajthy, L. Fesus, and Z. Bacso High content analysis of differentiation and cell death in human adipocytes Cytometry A 83 10 2013 933 943
12. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 2006 860 867
13. L.J. Wang, S.C. Ree, Y.S. Huang, C.C. Hsiao, and C.K. Chen Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs Prog. Neuropsychopharmacol. Biol. Psychiatry 40 2013 260 266
14. R. Ganguli, J.S. Brar, R. Garbut, C.C. Chang, and R. Basu Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole Clin. Schizophr. Relat. Psychoses 5 2011 75 79
15. T.S. Stroup, M.J. Byerly, H.A. Nasrallah, N. Ray, A.Y. Khan, J.S. Lamberti, I.D. Glick, R.M. Steinbook, J.P. McEvoy, and R.M. Hamer Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial Schizophr. Res. 146 2013 190 195
16. O.N. Karayal, P. Glue, M. Bachinsky, M. Stewart, P. Chappell, S. Kolluri, and I. Cavus Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder J. Psychiatr. Pract. 17 2011 100 109
17. N. Sasaki-Suzuki, K. Arai, T. Ogata, K. Kasahara, H. Sakoda, K. Chida, T. Asano, J.E. Pessin, F. Hakuno, and S. Takahashi Growth hormone inhibition of glucose uptake in adipocytes occurs without affecting GLUT4 translocation through an insulin receptor substrate-2-phosphatidylinositol 3-kinase-dependent pathway J. Biol. Chem. 284 2009 6061 6070
18. E.O. List, L. Sackmann-Sala, D.E. Berryman, K. Funk, B. Kelder, E.S. Gosney, S. Okada, J. Ding, D. Cruz-Topete, and J.J. Kopchick Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR-/-) mouse Endocr. Rev. 32 2011 356 386
19. K. Komossa, C. Rummel-Kluge, H. Hunger, S. Schwarz, P.S. Bhoopathi, W. Kissling, and S. Leucht Ziprasidone versus other atypical antipsychotics for schizophrenia Cochrane Database Syst. Rev. 2009 CD006627
20. S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, and A.W. Ferrante Jr. Obesity is associated with macrophage accumulation in adipose tissue J. Clin. Invest. 112 2003 1796 1808
21. M. Victoriano, R. de Beaurepaire, N. Naour, M. Guerre-Millo, A. Quignard-Boulange, J.F. Huneau, V. Mathe, D. Tome, and D. Hermier Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state Brain Res. 1350 2010 167 175
22. B. Gustafson, A. Hammarstedt, C.X. Andersson, and U. Smith Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 27 2007 2276 2283
23. V. Aguirre, E.D. Werner, J. Giraud, Y.H. Lee, S.E. Shoelson, and M.F. White Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action J. Biol. Chem. 277 2002 1531 1537
24. C. Kobashi, S. Asamizu, M. Ishiki, M. Iwata, I. Usui, K. Yamazaki, K. Tobe, M. Kobayashi, and M. Urakaze Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway J. Inflamm. (Lond.) 6 2009 25
25. A. Guilherme, J.V. Virbasius, V. Puri, and M.P. Czech Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes Nat. Rev. Mol. Cell Biol. 9 2008 367 377
26. T.A. Lett, T.J. Wallace, N.I. Chowdhury, A.K. Tiwari, J.L. Kennedy, and D.J. Muller Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications Mol. Psychiatry 17 2012 242 266
27. H. Hauner, K. Rohrig, J. Hebebrand, and T. Skurk No evidence for a direct effect of clozapine on fat-cell formation and production of leptin and other fat-cell-derived factors Mol. Psychiatry 8 2003 258 259
28. R. Roge, B.K. Moller, C.R. Andersen, C.U. Correll, and J. Nielsen Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr. Res. 140 2012 204 213
29. M.W. Schwartz, S.C. Woods, D. Porte Jr., R.J. Seeley, and D.G. Baskin Central nervous system control of food intake Nature 404 2000 661 671
30. B. Lee, and J. Shao Adiponectin and energy homeostasis Rev. Endocr. Metab. Disord. 15 2014 149 156